Canakinumab Ilaris®
The SHIKARI® Canakinumab portfolio provides one quantitative free-drug assay and two anti-canakinumab antibody assays for human serum or plasma. Each assay is presented according to its exact official product record.
Why Canakinumab is relevant to biological-drug monitoring research
Canakinumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Canakinumab is a fully human monoclonal antibody that selectively binds interleukin-1β (IL-1β), neutralising its interaction with the IL-1 receptor. Source ↗
Approved Indications
EMA-authorised uses include cryopyrin-associated periodic syndromes and other periodic-fever syndromes, Still’s disease and gouty arthritis in defined patients. EMA source ↗
Indication-Specific Exposure
EMA product information reports regimen- and indication-specific steady-state concentrations:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three complementary research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free canakinumab capable of binding IL-1β in human serum or plasma.
Sandwich-principle ELISA for quantitative determination of anti-canakinumab antibodies in human serum or plasma; the assay includes a confirmation-reagent procedure.
Sandwich-principle ELISA for qualitative detection of anti-canakinumab antibodies in human serum or plasma, reported as positive or negative according to assay-specific interpretation criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-CAN | CAN-FD-ILA | Quantitative Drug-Level Assay | Free canakinumab | Ligand-binding sandwich ELISA | 96 | 2–8°C |
| SHIKARI® S-ATCAN | CAN-QNS-ILA | Quantitative Anti-Drug Antibody Assay | Anti-canakinumab antibodies | Sandwich ELISA | 96 | 2–8°C |
| SHIKARI® S-ATCAN | CAN-QLS-ILA | Qualitative Anti-Drug Antibody Assay | Anti-canakinumab antibodies | Sandwich ELISA | 96 | 2–8°C |
Analytical specifications are summarized from the current official product records. The standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Which kit fits your research question?
Canakinumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Canakinumab assay and prepare regional quotation and delivery information.